Small-Molecule HGF/MET Positive Modulators Effectively Reduce Pain-Related Behaviors in a Rat Model of Diabetic Neuropathy

Jewel Johnston, PhD, Andrée-Anne Berthiaume, PhD, Robert Taylor, PhD, Kevin Church, PhD

Athira Pharma, Inc., Bothell, WA, USA

INTRODUCTION

- Roughly 60% of patients with diabetes mellitus have neuropathic pain[1]
- Neuropathic pain is largely caused by underlying damage to sensory neurons[2]
- Hepatocyte growth factor (HGF) and its receptor, MET, play a critical role in promoting neuroprotective, neurotrophic, and anti-inflammatory mechanisms[3-5]
- We have developed a platform of small molecule positive modulators of HGF/MET, two of which are ATH-1018 and ATH-1019

Figure 1. Positive Modulation of the HGF/MET Pathway Stimulates Downstream Signaling Pathways That May Provide Therapeutic Benefit in Peripheral Neuropathy



α2δ1, calcium channel subunit α2δ1; Akt, protein kinase B; ATF3, activating transcription factor 3; CSF1, macrophage colony-stimulating factor 1; CXCR4, chemokine receptor type 4; HGF, hepatocyte growth factor; IL-6, interleukin 6; MAPK, mitogen-activated protein kinase; NFκB, nuclear factor kappa B; P, phosphorylation; PI3K, phosphoinositide 3-kinase; PM, positive modulator; RAF, rapidly accelerated fibrosarcoma.

OBJECTIVE

To evaluate the efficacy of ATH-1018 and ATH-1019 in the treatment of neuropathic pain in a rat model of streptozotocin (STZ)-induced diabetic neuropathy

METHODS

Figure 2. Experimental Timeline



IV, intravenous; PO, by mouth; STZ, streptozotocin.

- Diabetes was induced in 6- to 8-week-old Sprague Dawley rats by a single dose of STZ (55 mg/kg intravenously [IV])
- Each study compared 4 doses of ATH-1018 (0.156, 0.625, 2.5, and 10 mg/kg by oral gavage [PO]; n = 13, each treatment group) or ATH-1019 (0.00625, 0.025, 0.1, and 1 mg/kg PO; n = 12, each treatment group)
- Each study had 3 control groups: a sham control that received vehicle rather than STZ (normal control), a diabetic neuropathic pain (DNP) control that received vehicle doses rather than drug treatment (DNP control), and a reference control group treated with pregabalin (30 mg/kg) (DNP + pregabalin)
- Mechanical allodynia was assessed using von Frey filaments (1.4, 4, 10, 15, 26, 48, and 60 g)

RESULTS

Figure 3. ATH-1018 and ATH-1019 Significantly Promoted Activation of MET In Vitro



When combined with subthreshold levels of HGF, treatment with (A) ATH-1018 or (B) ATH-1019 resulted in significantly increased levels of MET phosphorylation *in vitro* (1-way ANOVA with Dunnett's multiple comparisons vs HGF 1 ng/mL).

HGF, hepatocyte growth factor.

* $P < 0.05$; ** $P < 0.01$.

Figure 4. Confirmation of Diabetic Phenotype: Elevated Blood Glucose Levels on Day 4 After STZ Injection



Blood glucose levels were comparable across all diabetic neuropathy groups treated with either (A) ATH-1018 or (B) ATH-1019, and the normal control group had significantly lower blood glucose levels (1-way ANOVA with Dunnett's multiple comparisons vs DNP control).

BGL, blood glucose level; DNP, diabetic neuropathic pain; STZ, streptozotocin.

**** $P < 0.0001$.

Figure 5. Diabetic Animals Had Significantly Lower Body Weights Compared to Normal Control Animals



Nondiabetic normal controls had significantly higher body weights than DNP controls; no differences in body weights were noted between any of the diabetic groups receiving either (A) ATH-1018 or (B) ATH-1019 (2-way ANOVA with Dunnett's multiple comparisons vs DNP control).

**** $P < 0.0001$.

Figure 6. Treatment With ATH-1018 or ATH-1019 Significantly Reduced Mechanical Allodynia



(A) Animals treated with ATH-1018 exhibited a dose-dependent response (1-way ANOVA with Dunnett's multiple comparisons vs DNP control). (B) PWTs in animals treated with 10 mg/kg ATH-1018 were increased over diabetic controls by day 23. (C) Animals treated with ATH-1019 had significantly increased PWTs (1-way ANOVA with Dunnett's multiple comparisons vs DNP control). (D) PWTs in animals treated with 0.1 mg/kg of ATH-1019 were increased over diabetic controls by day 21.

AUC, area under the curve; DNP, diabetic neuropathic pain; PWT, paw withdrawal threshold.

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

- Across all tested doses of ATH-1018 and ATH-1019, a significant decrease in mechanical allodynia was seen, as indicated by increased paw withdrawal thresholds (PWTs) across the treatment period
- Treatment with ATH-1018 elicited a dose-dependent response, with higher doses exhibiting a highly significant increase in PWT area under curve (AUC) over the treatment period, and dosing with 10 mg/kg resulting in significant increase by day 23
- Improvement in PWT AUC over the treatment period was robust across tested doses of ATH-1019, with no clearly identifiable dose-dependent response, and treatment with ATH-1019 resulted in a significant increase in PWTs by day 21

Figure 7. Reduction in Mechanical Allodynia Persisted After Clearance of ATH-1018 and ATH-1019



(A) PWTs in animals treated with ATH-1018 were significantly increased compared with diabetic controls (1-way ANOVA with Dunnett's multiple comparisons vs DNP control). (B) PWTs in animal treated with ATH-1019 at higher doses were significantly increased compared with diabetic controls (1-way ANOVA with Dunnett's multiple comparisons vs DNP control).

DNP, diabetic neuropathic pain; PWT, paw withdrawal threshold.

* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.

- Pain was assessed on day 25 before dosing
- Both ATH-1018 and ATH-1019 are rapidly cleared from blood plasma, with $t_{1/2}$ being 0.5 to 1 hour (complete clearance in 3.5-7 hours), allowing PWT to be assessed before dosing to evaluate persistent effects
  - Because pregabalin has a $t_{1/2}$ of 6.3 hours (complete clearance in 44 hours), it was still present in blood plasma at the time of assessment, and PWT was not assessed for this control group
- PWT was significantly higher in animals treated with ATH-1018, with a clear dose-dependent response, even when mechanical allodynia was assessed before dosing
- Before dosing, animals given higher concentrations of ATH-1019 had significantly higher PWTs

References

1. Callaghan BC et al. *Curr Opin Neurol.* 2012;25:536-541.
2. Baron R et al. *Lancet Neurol.* 2010;9:807-819.
3. Ko KR et al. *Sci Rep.* 2018;8:8316.
4. Nicoleau C et al. *Stem Cells.* 2009;27:408-419.
5. Desole C et al. *Front Cell Dev Biol.* 2021;9:683609.

Acknowledgments

This study was sponsored by Athira Pharma, Inc. Medical writing support was provided by Katie Henderson, PhD of ApotheCom and funded by Athira Pharma, Inc.

Disclosures

Jewel Johnston, Andrée-Anne Berthiaume, Robert Taylor, and Kevin Church are employees and stockholders of Athira Pharma, Inc.

CONCLUSIONS

- Daily oral treatment with ATH-1018 or ATH-1019 in rats with STZ-induced diabetic neuropathy significantly reduced pain responses
  - Animals treated with ATH-1018 showed significant inhibition of mechanical allodynia
    - All tested doses produced significantly increased PWTs, with a clear dose-dependent response
  - Animals treated with ATH-1019 showed significant inhibition of mechanical allodynia
    - All tested doses produced significantly increased PWTs
- At day 25 (treatment day 10), animals showed significant inhibition of mechanical allodynia before receiving treatment with ATH-1018 or ATH-1019, suggesting that the compounds may have lasting disease-modifying effects, even once cleared from circulation

Based on these promising preclinical results, ATH-1018 and ATH-1019 are being developed as potential treatments for diabetic neuropathy and other neurological disorders

Supplemental methods, a recording of the author presenting the poster, and copies of this poster can be obtained through this QR code. These materials are for your personal use only and may not be reproduced without permission from the authors.

https://bit.ly/3KLz2qf

Athira PHARMA

Presented at the PNS 2022 Annual Meeting; May 14-17, 2022; Miami, Florida